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S U M M A R Y
Over the last decade, methicillin-resistant Staphylococcus aureus (MRSA) strains have emerged as serious
pathogens in the nosocomial and community setting. Hospitalization costs associated with MRSA
infections are substantially greater than those associated with methicillin-sensitive S. aureus (MSSA)
infections, andMRSA has wider economic effects that involve indirect costs to the patient and to society.
In addition, there is some evidence suggesting that MRSA infections increase morbidity and the risk of
mortality. Glycopeptides are the backbone antibiotics for the treatment of MRSA infections. However,
several recent reports have highlighted the limitations of vancomycin, and its role in themanagement of
serious infections is now being reconsidered. Several new antimicrobials demonstrate in vitro activity
against MRSA and other Gram-positive bacteria. Data from large surveys indicate that linezolid,
daptomycin, and tigecycline are almost universally active against MRSA. This review will brieﬂy discuss
the epidemiology, costs, outcome, and therapeutic options for the management of MRSA infections.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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journa l homepage: www.e lsev ier .com/ locate / i j idThe ongoing explosion of antibiotic-resistant infections con-
tinues to plague global healthcare.1 Methicillin-resistant Staphy-
lococcus aureus (MRSA) is at present the most commonly identiﬁed
antibiotic-resistant pathogen inmany parts of theworld, including
Europe, the Americas, North Africa, theMiddle East, and East Asia.2
Methicillinwas introduced in 1959 to treat infections caused by
penicillin-resistant S. aureus. In 1961 there were reports from the
UK of S. aureus isolates that had acquired resistance to methicillin,
and apart from a period during the early 1970s, the incidence of
this resistance has steadily increased, as data show from
continuing surveillance initiatives such as the National Nosoco-
mial Infection Surveillance Systemand the European Antimicrobial
Resistance Surveillance System.3–8
Hospital-acquired MRSA (HA-MRSA) strains are no longer
limited to hospitals, but have now spread to other healthcare
settings such as long-term care facilities (LTCFs). In a single-day,
point-prevalence study of a 180-bed LTCF, Furuno et al. found a
high prevalence of colonization by both MRSA (28%) and A.
baumannii (30%).9 In another study conducted in Spain, Manzur
et al. showed that the prevalence of MRSA colonization was 16.8%
(95% conﬁdence interval (CI) 14.9–18.8), varying from 6.7% to
35.8% (p < 0.001) among LTCFs.10
Another major change in the epidemiology of staphylococcal
infections is the rapid emergence of community-acquired MRSA
(CA-MRSA) strains since the late 1990s, particularly in the USA.11* Corresponding author. Tel.: +39 06 5594223; fax: +39 06 5594224.
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doi:10.1016/j.ijid.2010.05.003These involvepreviouslyhealthy individualswithouteitherdirect or
indirect association with healthcare facilities and have emerged as
a new and important public health problem.12 Differing from HA-
MRSA (which normally contain the type I, II or III staphylococcal
cassette chromosome mec – SCCmec), CA-MRSA isolates contain
type IV SCCmec.13 Some CA-MRSA isolates produce a toxin, Panton–
Valentine leukocidin (PVL), which may in part be responsible for
their increased virulence. CA-MRSA isolates have been associated
with a variety of clinical manifestations, ranging from mild skin
infections to lethal pneumonia and sepsis. Like methicillin-
susceptible S. aureus (MSSA) clinical isolates in the community,
themajority of CA-MRSA clinical isolates are recovered from skin or
soft tissue.14 Recently, Hota et al. observed that the incidence of
CA-MRSA skin and soft tissue infections (SSIs) increased from 24.0
casesper100000people in2000 to164.2 casesper100000people in
2005 (risk ratio = 6.84).15 CA-MRSA infection is transmitted from
person to person. Intrafamilial spread with subsequent onset of
clinical infections and outbreaks has been reported.15 Recently, new
strains of MRSA emerging from within the animal kingdom are
causing human infection. Historically, MRSA infections in compan-
ion animals involved strains resembling human nosocomial strains.
In this setting, the assumption was that the direction of spread had
been from man to animals. However, this situation is changing
rapidly, with some strains ofMRSA that are thought to have evolved
in animals – especially in pigs and horses – colonizing and infecting
human attendants.16–18
As with other multi-resistant infections, MRSA infections are
associated with high costs and extended hospital stay. On this
point, Engemann et al. observed that patients with surgical siteses. Published by Elsevier Ltd. All rights reserved.
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than did patients infected with MSSA (odds ratio (OR) 3.4, 95% CI
1.5–7.2). Patients infected with MRSA had a greater duration of
hospitalization after infection (median additional days = 5;
p < 0.001), although this was not signiﬁcant on multivariate
analysis (p = 0.11). Median hospital charges were US$ 29 455 for
control subjects, US$ 52 791 for patientswithMSSA SSI, and US$ 92
363 for patients with MRSA SSI (p < 0.001 for all group
comparisons). Patients with MRSA SSI had a 1.19-fold increase
in hospital charges (p = 0.03) and had mean attributable excess
charges of US$ 13 901 per SSI compared with patients who had
MSSA SSIs.19 In another study, Kopp et al. showed that patients
with MRSA infections had a trend toward longer hospital length of
stay (15.5 vs. 11 days; p = 0.05) and longer antibiotic-related
hospital length of stay (10 vs. 7 days; p = 0.003). The median
hospital cost associated with treatment of patients with MRSA
infections was higher compared with patients with MSSA
infections (US$ 16 575 vs. US$ 12 862).20 Cosgrove found that
both the median length of hospitalization after S. aureus
bacteremia for patients who survived and the median hospital
charges after S. aureus bacteremia were signiﬁcantly increased in
MRSA patients (7 vs. 9 days, p = 0.045; US$ 19 212 vs. US$ 26 424
dollars, p = 0.008). After multivariable analysis, compared with
MSSA bacteremia, MRSA bacteremia remained associated with
increased length of hospitalization (1.29-fold; p = 0.016) and
hospital charges (1.36-fold; p = 0.017). MRSA bacteremia had a
median attributable length of stay of 2 days and a median
attributable hospital charge of US$ 6916.21
There is some evidence suggesting that MRSA infection
increases morbidity, the risk of mortality, and costs. Cosgrove
et al. performed a meta-analysis to summarize the impact of
methicillin resistance on mortality in S. aureus bacteremia. The
authors described 31 studies on a total of 3963 patients with S.
aureus bacteremia. Analysis showed a signiﬁcant increase in
mortality associated with MRSA bacteremia (OR 1.93, 95% CI 1.54–
2.42; p < 0.001).22 In another meta-analysis, Whitby et al.
observed that bacteremia caused by MRSA was associated with
signiﬁcantly higher mortality rates than bacteremia caused by
MSSA (29% vs. 12%; p < 0.001).23 Melzer et al. observed that the
proportion of patients whose death was attributable to MRSA was
signiﬁcantly higher than that for MSSA (11.8% vs. 5.1%; OR 2.49,
95% CI 1.46–4.24; p < 0.001).24 Recently, Zahar et al. observed
similar results in ventilator-associated pneumonia (VAP) due to
MRSA. The authors showed that the crude hospital mortality rate
was higher for MRSA-infected patients than for MSSA-infected
patients (59.4% vs. 40%; p = 0.024).25 However, crude mortality is
the sum of mortality from infection plus the mortality of the
underlying diseases and the attributable role of the infection
remains unclear.
In this setting, the main prognostic factor associated with
mortality in patients withMRSA infections is inadequate antibiotic
therapy (IAT). IAT has been shown to be associated with an
increased mortality among patients with bloodstream infections,
nosocomial pneumonia including ventilator-associated pneumo-
nia, and more recently community-associated pneumonia.26,27
Time to initiation of effective antimicrobial therapy is a strong
predictor of mortality. Several studies underscore the importance
of selecting the appropriate initial antibiotic early in the course of
the infection.28 Thus a more rapid identiﬁcation of etiologic
pathogens and their antibiotic susceptibility proﬁles could help
reduce the administration of inadequate treatment.26
At present, blood culture is the gold standard for diagnosing
bacteremia, but it may take more than 2 days before results are
available. Furthermore, the sensitivity of blood cultures is
markedly reduced if blood samples are obtained during antimi-
crobial treatment. Therefore, the clinical impact of blood culturescan be limited. PCR detection of bacteremia directly in blood
samples, without prior cultivation, offers a fast alternative to the
blood culture method and is presumably unaffected by the prior
use of antibiotics. Louie et al. showed that PCR detected potentially
signiﬁcant bacteria and fungi in 45 cases compared to 37 by blood
culture. PCR detected the methicillin resistance (mecA) gene in all
three culture-conﬁrmedMRSA cases. More than 68% of PCR results
were conﬁrmed by blood, urine, and catheter culture.29 Peters et al.
evaluated the performance of real-time PCR assays for the
quantitative detection of S. aureus bacteremia directly in blood
samples, without prior cultivation. The sensitivity and speciﬁcity
for bacteremia of the S. aureus PCRwere 75% and 93%, respectively.
PCR ampliﬁcation reactions were positive for S. aureus for 10 (7%)
blood samples with negative blood cultures. Moreover, the use of
active surveillance cultures from patients for carriage of MRSA
facilitates an early contact isolation (and even treatment), thus
preventing spread in the hospital and reducing costs.30
Huang et al. determined the 18-month risk of MRSA infection
among 209 adult patients newly identiﬁed as harboring MRSA.
Twenty-nine percent of 60 patients developed subsequent MRSA
infections (90 infections). These infections were often severe.
Twenty-eight percent of infections (25 of 90) involved bacteremia,
and 56% (50 of 90) involved pneumonia, soft tissue infection,
osteomyelitis, or septic arthritis. Eighty percent of patients (48 of
60) with subsequent MRSA infection developed the infection at a
new site, and 49% of new MRSA infections (44 of 90) ﬁrst became
manifest after discharge from the hospital.31 Datta et al. deter-
mined the duration of MRSA colonization in a large population of
patients who were retested at hospital admission after a prior
episode for which an MRSA test yielded a positive result. Among
281 prevalent carriers, 65 (23%) developed a total of 96 discrete
and unrelatedMRSA infections in the year after their identiﬁcation
as prevalent carriers. The most common infections were pneumo-
nia (accounting for 39% of MRSA infections), soft tissue infection
(14%), and central venous catheter infection (14%). Twenty-four
percent of all infections involved bacteremia. Thirty-eight MRSA
infections occurred during a new hospitalization, and 32 (84%) of
these infections were the reason for admission to the hospital.
MRSA contributed to 14 deaths, with six of these deaths deemed to
be attributable to MRSA. Harboring MRSA for <2 years and MRSA
colonization at the time of detection as a prevalent carrier were
predictive of subsequent infection with MRSA.32 More recently,
Robicsek et al. showed that in patients previously hospitalized for
anMRSA infection, the rate of persistent colonization during year 1
was 48.8% (95% CI 45.8–51.7%), during year 2 was 28.2% (95% CI
21.6–35.5%), during year 3 was 23.0% (95% CI 15.2–32.5%), and
during year 4 was 21.2% (95% CI 13.1–31.4%).33
The same group analyzed the effect of large-scale expanded
surveillance for MRSA – PCR nasal surveillance for MRSA followed
by topical decolonization therapy and contact isolation – on HA-
MRSA disease. The authors showed a statistically signiﬁcant
decrease in theMRSA disease rate during hospitalization and in the
30 days after discharge.34 However, uncertainties remain regard-
ing the use of universal surveillance. In the same period, Harbarth
et al. found that a universal, rapid MRSA admission screening
strategy did not reduce nosocomial MRSA infection in a surgical
department with endemic MRSA prevalence but relatively low
rates of MRSA infection.35
There is great controversy over the current utility of the
backbone antibiotics – glycopeptides – for the treatment of MRSA
infections.36 The poor pharmacokinetic/pharmacodynamic param-
eters, with poor tissue distribution, slow cidal activity and high
protein binding predict poor patient outcome even without the
advent of resistant strains. These facts may explain the higher
mortality of MRSA infections and the poorer outcome even of
MSSA infections when treated with vancomycin. Moreover, there
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minimum inhibitory concentration (MIC) has a real impact on
patient outcome.37 In a 5-year period microbiological study, Wang
et al. observed that the percentage of S. aureus isolates with a
vancomycin MIC of 1mg/ml in 2004 was signiﬁcantly higher than
the percentage of isolates in 2000 (70.4% vs. 19.9%; p < 0.01).38 In a
small study, Sakoulas et al. found a statistically signiﬁcant
relationship between treatment success with vancomycin and
decreases in both vancomycin MICs (0.5 mg/ml vs. 1.0–2.0 mg/
ml; p = 0.02) and degree of killing (reduction in log10 CFU/ml) by
vancomycin over 72 h of incubation in vitro (p = 0.03). For MRSA
isolates with vancomycin MICs 0.5 mg/ml, vancomycin was
55.6% successful in the treatment of bacteremia, whereas
vancomycin was only 9.5% effective in cases in which vancomycin
MICs for MRSA were 1–2 mg/ml.39 In a another study comparing
infections caused by MRSA with a vancomycin MIC of 2mg/ml
with infections due toMRSAwith aMIC of<2mg/ml, responsewas
signiﬁcantly lower (62% vs. 85%; p = 0.02) and infection-related
mortality was higher (24% vs.10%) in the high MIC group. In
addition, a highMIC for vancomycin was an independent predictor
of poor response in multivariate analysis of these MRSA infec-
tions.40 More recently, Soriano et al. showed a signiﬁcantly higher
mortality for this disease when vancomycin was used empirically
and the vancomycin MIC was 2 mg/ml.41 In patients with
bacteremia, Lodise et al. showed that vancomycin MICs of
>1.5mg/ml had a 2.4-fold increase in failure compared to patients
with MICs of <1.0 mg/ml (p = 0.049). In the Poisson regression
analysis, a vancomycin MIC of >1.5mg/ml was independently
associated with failure (adjusted risk ratio 2.6, 95% CI 1.3–5.4;
p = 0.01).42 Therefore, clinical MRSA strains with high vancomycin
MIC values (2 mg/ml) require aggressive empirical therapy to
achieve trough concentrations 15 mg/l.43
More recently, a Consensus of the American Society of Health-
SystemPharmacists, the Infectious Diseases Society of America, and
the Societyof InfectiousDiseases Pharmacists suggested that trough
serum vancomycin concentrations in that range should achieve an
area under the curve (AUC)/MIC ratio of400 inmost patients if the
MIC is 1 mg/l. In order to achieve rapid attainment of this target
concentration for seriously ill patients, a loading dose of 25–30mg/
kg can be considered. However, a targeted AUC/MIC of 400 is not
achievable with conventional dosing methods if the vancomycin
MIC is 2 mg/l in a patient with normal renal function.44
Newer antibiotics with activity against MRSA have been
introduced: quinupristin/dalfopristin and linezolid in 1999–
2000, and more recently, tigecycline and daptomycin.
Linezolid possesses bacteriostatic activity against MSSA and
MRSA. The unique mechanism of action involves inhibition of
bacterial protein synthesis through binding to the domain V
regions of the 23S rRNA gene. In a subset analysis of patients with
surgical-site MRSA infections, complicated skin and skin-structure
infections and nosocomial MRSA pneumonia, but not in patients
with bacteremia, this drug demonstrated superiority over vanco-
mycin.45 The MIC50/90 of linezolid against MRSA have been
reported to be 1–2 mg/ml in different studies against strains
collected from a distinct part of the world.46 Its complete
bioavailability after oral administration allows effective oral
treatment. However, use of this drug for more than 4 weeks
may be accompanied by thrombocytopenia and both peripheral
and optic neuropathy.
Tigecycline is bacteriostatic against most pathogens but has a
broad spectrum of antimicrobial activity and enhanced penetra-
tion into many tissues. It acts by binding to the 30S ribosomal
subunit blocking the entry of amino-acyl transfer RNA into the
acceptor site. This leads to prevention of protein synthesis and
bacterial growth. All of the staphylococci tested were inhibited by
2mg/ml of tigecycline or less. Against MSSA and MRSA (includingcommunity-acquired strains), the tigecycline MIC90 was 0.12 and
0.25mg/ml, respectively.47 Tigecycline is only available as an
intravenous preparation. It provides parenteral therapy for
complicated skin/skin-structure and intra-abdominal infections.
The only prominent adverse effects are associatedwith tolerability,
most notably nausea and vomiting.
Daptomycin is a new lipopeptide antibiotic with activity
against S. aureus (including methicillin-resistant strains). The
mechanism of action is unique as daptomycin causes a calcium
ion-dependent disruption of bacterial cell membrane potential,
resulting in an efﬂux of potassium which inhibits RNA, DNA, and
protein synthesis. Rare instances of resistance have occurred in
clinical trials, although the mechanism of resistance has not yet
been identiﬁed. Several microbiological studies suggest that the
breakpoint of daptomycin should be less than 1mg/ml for S. aureus
(bothMRSA andMSSA).48 In recent years, some reports have linked
increasing vancomycin MICs to increasing daptomycin MICs.49
Although the mechanism is unclear, the report by Cui et al.
suggests that thick cell walls induced by the glycopeptide impair
the diffusion of daptomycin, amoleculewith amolecularweight of
>1600 Da, to target sites in the cell membrane.50 However, most of
these patients with daptomycin failure had deep-seated infections
associated with a high burden of infecting organisms, commonly
with the presence of a biomedical device or dead tissue with poor
blood perfusion.51 In early trials, daptomycin administered twice
daily caused increases in serum creatine phosphokinase levels.
However, myopathy was reversible upon cessation of the drug.52
Investigations of other drugs are at an advanced stage.
Dalbavancin, telavancin, and oritavancin are new glycopeptides
that have superior pharmacodynamic properties compared to
vancomycin.53 Ceftobiprole is the most advanced anti-MRSA
cephalosporin in the pipeline, already approved for clinical use
in some countries (e.g., Canada and Switzerland). Unlike the b-
lactams that are currently available in clinical practice, ceftobi-
prole binds to, and effectively inhibits, PBP2a of methicillin-
resistant staphylococci. Iclaprim is the only new diaminopyrimi-
dine derivative that targets bacterial dihydrofolate reductase.
Owing to its modiﬁed structure, iclaprim retains strong inhibitory
activity against trimethoprim-resistant dihydrofolate reductase
enzymes, which constitute the most important mechanism of
acquired resistance against trimethoprim in S. aureus.54
Future alternative approaches to combat infection are antibodies
that target speciﬁc virulence systems, as well as a variety of newly
discovered small molecules that block bacterial attachment,
communication systems, or important regulatory processes associ-
ated with virulence gene expression.55
A capsular polysaccharide-based vaccine showed promise in an
initial phase III trial in hemodialysis patients, but was found to be
ineffective in a conﬁrmatory trial.56 Likewise, a human immuno-
globulin G preparation known as INH-A21 with elevated levels of
antibodies to the staphylococcal surface adhesins ClfA and SdrG
made it into phase III testing, where it failed to show a clinical
beneﬁt in neonates.57 However, a number of novel antigens are in
pre-clinical trials, including cell wall-anchored adhesins, surface
polysaccharides, and exotoxoids.58
Finally, the use of signal molecule-based drugs to attenuate
bacterial pathogenicity rather than bacterial growth is attractive.
Promising quorum sensing inhibitor (QSI) compounds have been
shown to make bioﬁlms more susceptible to antimicrobial
treatments, and are capable of reducing mortality and virulence,
as well as promoting clearance of bacteria in experimental animal
models of infection.59 More recently, in a rat graft model,
hamamelitannin prevented device-associated infections in vivo,
including infections caused by MRSA strains.60
In conclusion, the prevalence of MRSA infection is increasing in
many parts of the world. There are currently many effective drugs
G. Ippolito et al. / International Journal of Infectious Diseases 14S4 (2010) S7–S11S10to treat resistant S. aureus infections andmany promising agents in
the pipeline. Nevertheless, S. aureus remains a formidable
adversary against which there are frequent treatment failures.
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